Globus Medical Inc. Class A Common Stock vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $18 (market cap $69.79B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 6.8× Globus Medical Inc. Class A Common Stock's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.34% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 3 Days on average.
| GMED | NWG | |
|---|---|---|
Market Cap | $10.25B | $69.79B |
Volume | 1,108,124 | 3,183,982 |
Sector | Health | Financials |
52-Week High | $96.82 | $19.42 |
52-Week Low | $58.33 | $13.89 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $9.76B | $142.57B |
Dividend Yield | — | 5.34% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NatWest Group (NWG) trades at $17.65, up 2.38% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a low P/E of 8.94 and robust profitability with a net income margin of 36.24%. Recent earnings have consistently beaten expectations, and analyst sentiment is positive, with a 'Moderate Buy' consensus. The company has upgraded its 2026 guidance and accelerated share buybacks, supported by healthy revenue growth and improving deposit margins.
The outlook for NWG is favorable, driven by earnings momentum and supportive analyst coverage, though risks include negative cash flow trends and potential regulatory scrutiny. The stock presents a value opportunity given its attractive valuation and strong return on equity, but investors should monitor execution on profitability targets and macroeconomic impacts on the banking sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →